on chart 69 real breakout.63 a big sell .Barrons a short while ago were positive on it.Downgrades create a buying opportunity.I also have been investing for 50 years ( do you feel same way I do that mkt no longer for us little guys with high frequency trading)
Sentiment: Strong Buy
STJ is a a great company - There are a bunch of analysts that are backing up this sentence. It is somewhat strange that this morning a downgrade came out , while on the same week couple of good articles are out about the future of the company. On the same week the company decided to increase it's dividend. Would a board increase the dividend if they thought that future situation is worse then the current situation ?
My 50 years of experience tell me - some are buying now intensively . What do you think ?
Well said......need more spiritual prayers...look up St Expeditus or some call him St Expeito.....he will deliver your spiritual request to the Virgin Mary on your behalf! God bless you !!!
Would you recommend a experienced college educated person to join/work at St Jude Medical operation in Westford, MA?
Does this site have a positive work environment, does management treat their employees as a valuable asset? How is this work vs.home life ratio?
May the Sacred Heart of Jesus be adored, glorified, loved and preserved throughout the world, now and forever. Sacred Heart of Jesus pray for us. Saint Jude Worker of miracles pray for us. Saint Jude help of the hopeless pray for us.
Bad news has been factored into this stock before earnings. Approaching 52 week low. Buy light lite and penny beat on earnings was better then expected. International drag has already been factored into this stock and can't believe the brutal drop today on something that was a forgone conclusion here. Strong buy at these levels.
Sentiment: Strong Buy
St. Jude's (STJ) new CardioMEMS heart failure monitoring device makes it the most attractive stock among the top three heart-device companies, says Needham, which initiates coverage of STJ with a strong buy. With hospitals under pressure to reduce heart failure readmissions plus a new Medicare add-on payment, CardioMEMS is poised to drive sustainable 8%-10% EPS growth for STJ, Needham says. The firm also starts Medtronic (MDT) at a buy and Boston Scientific (BSX) at hold. It says growth for the sector is shifting to new products and emerging markets.